Navigation Links
Arpida Announces Conference Call on 17 April
Date:4/15/2008

REINACH, Switzerland, April 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it will host a conference call on Thursday 17 April 2008 at 8.30am CET. In this conference call, a leading expert will discuss the medical need and developments in the area of anti-infective drugs as well as the outcome of a recent meeting of the Anti-Infective Drugs Advisory Committee. During that meeting, the committee discussed product development and clinical trial design for both mild/moderate and moderate/severe community acquired pneumonia (CAP). A primary objective for the committee deliberations was to discuss issues relating to clinical trial design.

During the conference call, Arpida will also discuss the clinical data from the ASSIST-1 and ASSIST-2 trials with intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI). In addition, the pooled analysis of the clinical data from these two pivotal Phase III trials will be discussed. Part of the data has already been published in earlier press releases, some additional statistical data, not previously published, will also be discussed. All data, as well as the dial-in details, will be made available via a press release on 17 April, prior to the conference call.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been co
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24...Nasdaq: DCGN ) today announced the approval of all... Court for the District of Delaware,(the "Bankrupt...ition for,relief under Chapter 11 of the United St..., The orders issued by the Bankruptcy Court...
(Date:11/24/2009)..., SEATTLE, Nov. 24 Blue Marble Ene... Odessa Public Development Authority (OPDA) were r...ommunity Economic Revitalization Board (CERB) in a...,s first specialty biochemical biorefinery in Linc...ificantly speed the development of our biorefinery...
(Date:11/24/2009)..., DUBLIN, November 24 /PRNewswire-FirstCall/ ...al specialty biopharmaceutical company, today,anno...Medicines Agency for,velaglucerase alfa, the compa... the treatment of Type 1 Gaucher disease. This is ...alfa that has been submitted, with previous,submis...
(Date:11/24/2009)... Program Connects Customers with Pa...llected with DNA Genotek Products , ... DNA Genotek , a leading provider of products for...reparation, today announced its new global partner...nts for DNA Genotek,s partner community and is des...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...ing high purity Type B silica, Tosoh has introduce...e treatment procedures and carbon content levels ,...de range of sample types. , , I... octadecylsilane (ODS) chemistries have been , ...ized properties for select , subsets of c...
... It is well known in HPLC that columns packed wit...at the expense of higher back pressure compared to...The gain in efficiency is usually traded , ...ults in shorter analysis , times and lowe...nes of 5 micron TSK-GEL ODS-100V and ODS-100Z colu...
...public www.dataapex.com , e-mail: vins@dat...V, Bratislava, Slovak Republic, , ...ibution of polymers by the liquid chromatographic ...ectors is a simple, affordable solution for proces...,synthetic and natural polymers. Absolute methods ...
Other Biology Technology:TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 2TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds 3Three Micron TSK-GEL ODS-100V Columns for High Throughput LCMS 2Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 2Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 3Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 4Practical Aspects of Evaluation of Chromatographic Data in Size Exclusion Chromatography 5
(Date:11/24/2009)...may help gut bacteria bind to the gastrointestinal...ducers to identify strains that are likely to be o...nteract with cells lining the gut to have a benefi... gut they are more likely to stick around long eno...e from the Institute of Food Research. IFR is an ...
(Date:11/24/2009)... -- The Wildlife Conservation Society (WCS) announ...ng population of Siberian tigers has likely declin...g and habitat loss. , WCS says the r...eeds to be done to protect remaining populations o...port was released by the Siberian Tiger Monitoring...
(Date:11/24/2009)..., The presence of increased body fat, and there...he blood, hinders the loss and maintenance of body...versity of Navarra conducted by Estbaliz Goyeneche... The project, entitled "A nutrigenetic and nutrige...ght and inflammation," examines how the individual...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2Report shows dramatic decline in Siberian tigers 2It can be predicted the reaction obese patients will have to a diet 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 1Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 3Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 4Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 5Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 6Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 7Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 1Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 2Frost 26 Sullivan European Gastroenterology Technology Implementation of the Year Award Bestowed on Crospon 50479 3A young brain for an old bee 9076 1A young brain for an old bee 9076 2
...tiple strains of the flu virus, circulating in a p...nes and create a new virus, one capable of infecti...he open-access journal PLoS Biology. This finding ...which viral strains will attack during upcoming fl..., In the first large-scale effort to sequence the ...
...a clever bit of biology called site-specific recom...to another organism, and perform a sort of graftin...into a chromosome of the target cell. The process ...at cause drug resistance or transmit viruses that ...kemias or other cancers. , But what do the surgeon...
... research on a bacterium that can survive encounte...ned scientists, belief that these plentiful white ... our immune system will permit or prevent bacteria...released today online in The Journal of Immunology...ories (RML), part of the National Institute of All...
Other Biology News:Enlisting genomics to understand flu evolution 2Brown-Harvard team solves mobile DNA's surgical sleight-of-hand 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-GPCR G2A Polyclonal Antibody, Unconjugated from Abcam
Anti-6-keto Prostaglandin F1 alpha (EIA Antiserum) Antibody, Unconjugated from Cayman Chemical
BD FACSCanto flow cytometer from BD Biosciences - Immunocytometry Systems
Biology Products: